Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, announce that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer and subsequent merger. The acquisition complements and further strengthens Immedica’s global rare disease business by adding ZTALMY® (ganaxalone) oral suspension, CV, a neuroactive steroid gamma-aminobutyric acid (GABA)-A receptor positive modulator.
Read the full article: Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc. //
Source: https://www.businesswire.com/news/home/20241230307666/en/Immedica-to-Acquire-Biopharmaceutical-Company-Marinus-Pharmaceuticals-Inc.